Glaucoma

Glaucoma is a progressive optic neuropathy characterized by structural damage to the optic nerve and corresponding visual field loss, often associated with elevated intraocular pressure. As one of the leading causes of irreversible blindness worldwide, it remains a central focus at every major Ophthalmology Conference. This topic addresses the pathophysiology, risk factors, early detection strategies, and evolving treatments aimed at preventing permanent optic nerve damage and preserving long-term visual function.

Glaucoma encompasses a spectrum of conditions, including primary open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, and secondary glaucomas related to trauma, inflammation, or steroid use. The disease is frequently asymptomatic in its early stages, making routine screening essential for timely diagnosis. Structural assessment through optical coherence tomography, retinal nerve fiber layer analysis, and optic disc imaging complements functional evaluation using automated perimetry. Early identification of progressive change is critical in preventing irreversible vision loss.

Management strategies focus primarily on lowering intraocular pressure through pharmacologic, laser, or surgical approaches. Topical medications such as prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, and combination therapies remain first-line interventions. Selective laser trabeculoplasty offers a minimally invasive alternative for pressure reduction, while advanced surgical techniques including minimally invasive glaucoma surgery provide effective control with fewer complications. Individualized treatment planning considers patient age, disease severity, progression rate, and systemic health factors.

Research in glaucoma extends beyond pressure control, exploring neuroprotective strategies that directly target retinal ganglion cell survival. Investigations into vascular dysregulation, genetic predisposition, and biomarker development are deepening understanding of disease mechanisms. Artificial intelligence–assisted imaging tools enhance early detection and risk stratification, supporting precision medicine approaches.

Public health initiatives emphasize awareness campaigns and screening programs, particularly in high-risk populations such as the elderly and individuals with a family history of glaucoma. Long-term patient adherence and monitoring are essential components of effective disease management. Through interdisciplinary collaboration and continuous innovation, advances in glaucoma care aim to slow progression and protect visual independence worldwide.